Cancer progression and treatment resistance are promoted by the immunosuppressive properties of the tumor microenvironment, which can be overcome in select cases by the recently developed immune checkpoint blockade therapy comprising the suppression of cytotoxic T lymphocyte–associated protein 4 (CTLA-4) and of the PD1/PD-L1 inhibitory pathway. This evidence concerns the gene CD274 and neoplasm.